Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
GLP-1 drugs like semaglutide are emerging as powerful tools to combat the metabolic side effects of antipsychotic medications in people with schizophrenia. A landmark meta-analysis of 95 trials found semaglutide led to nearly 11 kg of weight loss — and a separate large cohort study linked GLP-1 use to 24% fewer psychiatric hospitalizations. Access and insurance coverage remain significant barriers to wider use.
People with schizophrenia already face a life expectancy 10–25 years shorter than the general population, largely due to metabolic complications from antipsychotic medications. Now, two major studies suggest GLP-1 receptor agonists could be a game-changer — not just for the waistline, but potentially for psychiatric outcomes too.
A landmark network meta-analysis published in JAMA Psychiatry, covering 95 trials and nearly 6,000 participants, ranked semaglutide (Wegovy) as the most effective pharmacological intervention for antipsychotic-associated weight gain, followed by liraglutide, topiramate, metformin, and exenatide. A separate large retrospective cohort study in Lancet Psychiatry (October 2026) found GLP-1 use was associated with 24% fewer psychiatric hospitalizations and 29% fewer psychiatric ED visits in patients with schizophrenia and type 2 diabetes — though experts caution that causality has not been established and RCTs are needed.
By the Numbers:
Why it matters: Despite compelling evidence, insurance coverage gaps continue to block access for many patients with schizophrenia — a population already among the most medically vulnerable. Experts are calling for a paradigm shift: treating metabolic weight gain not as an inevitable side effect, but as a preventable driver of morbidity and premature death.
